Galectin Therapeutics Inc. is a biotechnology company focused on the discovery and development of therapies for chronic liver disease and cancer. The company applies carbohydrate technology to target galectin proteins, which are key mediators of biologic and pathologic function. Its lead development program is belapectin (GR-MD-02), a proprietary polysaccharide polymer that inhibits galectin-3. Belapectin is in clinical trials for Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis, severe atopic dermatitis, moderate-to-severe plaque psoriasis, and as a combination immunotherapy for advanced melanoma. The company seeks partners as programs advance to support resource-intensive development phases.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage galectintherapeutics.com
Sector Healthcare IR page investor.galectintherapeutics.com
Tags
galectin-3 inhibitors, carbohydrate-based drugs, chronic liver disease, mash cirrhosis, cancer immunotherapy, melanoma, atopic dermatitis, plaque psoriasis, fibrosis, inflammatory diseases, belapectin, GR-MD-02, NAVIGATE study, KEYTRUDA
Press page —

Metrics

Valuation  
Market cap $ 391.395M
Market cap (USD) $ 391.395M
P/E -11.41
PEG —
P/BV -11.13
P/S —
P/OCF -26.79
P/FCF -16.39
Dividend yield —
Turnover / mcap —
Returns  
ROE 24.1%
ROI -530.1%
ROIC -259.0%
Profit margin —
Growth  
Revenue growing —
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 11
Quality score -41.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002
Assets 19.532M 17.495M 28.2M 21.285M 41.827M 29.6M 48.467M 9.006M 4.161M 15.795M 26.408M 29.677M 10.713M 9.561M 6.612M 6.3M 436K 704K 1.782M 6.363M 4.963M 11.11M 8.002M 2.283M
Net profit -30.836M -47.047M -41.066M -38.776M -30.527M -23.465M -13.294M -13.9M -16.235M -21.436M -20.027M -15.788M -12.088M -9.675M -10.915M -5.629M — — — — — — — —
Free cash flow -23.875M -41.767M -32.965M -31.056M -24.308M — — — — — -16.983M — — -7.505M -5.681M — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002
Share price 4.16 1.29 1.66 1.13 2.07 2.24 2.86 3.43 3.34 0.98 1.64 3.47 8.08 2.11 1.21 — — — — — — — — —
Price performance 12m 2.22 -0.22 0.47 -0.45 -0.08 -0.22 -0.17 0.03 2.41 -0.4 -0.53 -0.57 2.83 0.74 — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 0.00 39,000 44,000 8,000 106,000 66,000 19,000 22,000
Cash and deposits (USD) 15.4M 3.05M 8.25M 47.5M 27.1M 39.6M 18.6M 25.7M 15.1M 17.7M
Intangible assets (USD) 1,000 0.00 0.00 — — — — — — —
Right-of-use assets (USD) — — — — — 7,000 86,000 53,000 16,000 22,000
Cash flow detail
Operating cash flow (USD) -16.4M -15.9M -10.2M -10.8M -20.6M -24.3M -31.1M -33M -41.8M -23.9M
Change in payables (cash effect) (USD) 2.42M -812,000 -1.09M 997,000 2.54M 3.69M 4.24M 2.67M -2.07M -6.04M
Share-based compensation (USD) 2.48M 1.1M 4.45M 1.68M 1.8M 2.08M 2.87M 2.26M 2.45M 1.66M
Income detail
Research and development expense (USD) 15.3M 11.7M 6.47M 7.47M 18M 23.8M 31.7M 32.1M 36.6M 14.3M
↳ 5y CAGR +34.0% +21.0% +2.6% -2.4% +6.5% +9.2% +22.0% +37.8% +37.4% -4.5%
Reported Mar 28, 2017 Mar 6, 2019 May 10, 2019 Mar 16, 2020 Mar 31, 2021 Mar 31, 2022 Mar 30, 2023 Mar 29, 2024 Mar 31, 2025 Mar 31, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

NORCROSS, Ga., November 16, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2026.

“New analyses were presented at AASLD, marking the fourth consecutive major liver conference where Galectin data was included in an oral presentation. We were extremely pleased by the positive feedback received on the oral presentation as well as the two poster presentations and are excited that our data was included in the AASLD conference highlights and the portal hypertension debrief,” said Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics. “We would like to thank all the authors for their contributions but especially to Dr. Naim Alkhouri for the oral presentation on ANTICIPATE-NASH.”

Mr. Lewis continued, “As previously disclosed, we submitted our registrational Phase 3 protocol to FDA in the third quarter after reaching alignment on primary elements of the planned Phase 3 trial design.

  • Galectin Therapeutics will present new clinical findings at American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Denver. These results will be covered in one oral presentation and two posters including a Poster of Distinction.

  • Belapectin treatment was associated with lower variceal incidence than placebo across all risk categories, i.e. ANTICIPATE-NASH and Baveno risk categories in the NAVIGATE trial, supporting its potential to reduce portal hypertension–related risk.

  • These findings support using baseline noninvasive risk assessments for patient enrichment in the planned Phase 3 registration trial and to better evaluate belapectin’s potential to prevent disease progression in patients with MASH cirrhosis and portal hypertension.

NORCROSS, Ga., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it will deliver an oral presentation and present two posters, one of which has been recognized as a Poster of Distinction, at the AASLD Liver Meeting 2026, which is taking place on November 5-9, 2026, in Denver, Colorado.

Oral Presentation: ANTICIPATE-NASH Risk Stratification in the NAVIGATE Trial This oral presentation will review the potential utility of ANTICIPATE-NASH risk stratification, a validated noninvasive tool to predict variceal development and assess belapectin treatment effect. In the NAVIGATE trial, belapectin treatment was associated with a favorable shift toward lower ANTICIPATE-NASH predicted clinically significant portal hypertension (CSPH) risk at 18 months, with a net 15.9% placebo-adjusted improvement (p=0.04). Variceal incidence increased with higher CSPH probability yet was consistently lower in patients treated with belapectin vs placebo across all baseline risk categories. The findings suggest that belapectin may reduce CSPH risk and potentially future hepatic decompensation.

Poster of Distinction: Baveno and ELF Risk Stratification in the NAVIGATE Trial Baveno VII criteria and ELF score enable risk stratification for CSPH and risk of decompensation, respectively. This Poster of Distinction highlights the relationship between baseline Baveno VI and ELF risk categories and incidence of varices and belapectin treatment effect. Baveno stratification demonstrated increasing incidence of varices with greater portal hypertension severity. Within each category, incidence of varices was lower in patients treated with belapectin vs placebo. Similarly, higher baseline ELF risk was associated with a stepwise increase in new varices, with highest risk ELF i.e. ≥ 11.3 showing significantly greater incidence than lower-risk categories. These results support utilizing these methods of risk stratification to identify higher-risk patients and potentially improve treatment-effect detection in the planned Phase 3 trial in MASH cirrhosis.

Poster Presentation: Baveno VII and ANTICIPATE-NASH in the Phase 2b GT-026 Trial This poster presentation provides an overview of the analysis evaluating the correlation between Baveno VII criteria and ANTICIPATE-NASH, two noninvasive tests, with actual HVPG results the invasive gold standard for portal hypertension measurement. Both noninvasive tests showed moderate agreement with HVPG-defined CSPH in patients with compensated MASH cirrhosis. Baveno VII demonstrated slightly better concordance and broader risk stratification than ANTICIPATE-NASH. Together, results suggest that noninvasive tools can be used to identify CSPH and enrich the clinical trial population in MASH cirrhosis.

“Developing varices is an important clinical event in patients with compensated MASH cirrhosis, and these analyses from the NAVIGATE and GT-026 studies provide important insights into how noninvasive tools can identify patients at greater risk of varices development” said Naim Alkhouri, M.D., FAASLD; Chief Medical Officer at Summit Clinical Research and presenting author. “Importantly, across these analyses, belapectin was associated with lower variceal incidence and a favorable shift in predicted CSPH risk, supporting further evaluation of these approaches to enrich patient selection and assess treatment effect in a future Phase 3 trial.”

“These risk stratification analyses strengthen our understanding of how noninvasive risk-stratification tools can be extremely useful to identify patients at greater risk of variceal development and inform our planned Phase 3 design,” stated Khurram Jamil, M.D., Chief Medical Officer at Galectin Therapeutics. “Together with the HVPG analyses, the results give us a rigorous, noninvasive framework that we plan to incorporate in the planned Phase 3 trial, to enrich the patient population and increase our probability of success to detect the effect of belapectin on variceal prevention.”

“We are pleased to present these results at the Liver Meeting this year, demonstrating the depth and scientific value of the NAVIGATE dataset and providing additional insights into the potential of belapectin to modify disease progression in patients with MASH cirrhosis and portal hypertension,” added Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics. “With the recent Phase 3 protocol submission to the FDA, we continue to advance our trial initiation activities while in parallel evaluating strategic partnerships for belapectin’s next phase of development.”

About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis and portal hypertension, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.

Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect”, “look forward”, “believe”, “hope” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not produce positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company’s current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.

Company Contact: Jack Callicutt, Chief Financial Officer (678) 620-3186 [email protected]

Investors Relations Contact: Kevin Gardner [email protected]

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.

<< Back

NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver Meeting 2026. The Company will deliver three presentations, including an oral presentation, a Poster of Distinction presentation, and one poster presentation, highlighting new risk analyses on noninvasive prediction of variceal development from the NAVIGATE and GT-026 Phase 2b trials of belapectin for the treatment of MASH cirrhosis and portal hypertension. The meeting will be held November 5-9, 2026, in Denver, Colorado.

In addition, the Company also announced today that it has submitted a registrational protocol for the Phase 3 trial of belapectin for the prevention of disease progression in patients with MASH cirrhosis and portal hypertension to the U.S. Food and Drug Administration (FDA).

“We are excited to have our ANTICIPATE-NASH analysis selected for oral presentation and the recognition of our Baveno and ELF analysis as a Poster of Distinction. These selections reflect not only the depth of the NAVIGATE trial datasets but also underscores the importance of non-invasive assessments in diagnosis of portal hypertension in patients with MASH cirrhosis who are at increased risk of developing serious complications such as varices. This represents the fourth consecutive major liver meeting where the Company has been selected for an oral presentation, and I want to thank our entire team led by Dr. Khurram Jamil, our Chief Medical Officer, for their efforts in this achievement. We have also submitted the registrational Phase 3 protocol, an important step forward in the advancement of our belapectin program for patients who today have no approved treatment options,” said Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics.

Presentation Details Oral Presentation

**Title:**ANTICIPATE-NASH Risk Stratification Predicts Variceal Development in Compensated MASH Cirrhosis: Results from the NAVIGATE Trial **Publication Number:**0253 **Presenter:**Naim Alkhouri, M.D., FAASLD **Date & time:**November 8, 2026, 9:15 am - 9:30 am MST

Poster Presentations

Poster of Distinction: **Title:**Baseline Baveno Portal Hypertension and ELF Risk Stratification Predict Variceal Development in Compensated MASH Cirrhosis: Findings from the NAVIGATE Trial **Session:**MASLD/MASH - Therapeutics: New Agents and Approved/Available Agents **Presenter:**Naim Alkhouri, M.D., FAASLD **Date & time:**November 7, 2026 at 12:00 pm - 1:00 pm MST

**Title:**Correlation of Baveno VII and ANTICIPATE-NASH Noninvasive Models with HVPG in Patients with MASH Cirrhosis: Findings from a Phase 2b Belapectin Trial **Session:**Portal Hypertension and Other Complications of Cirrhosis **Presenter:**Naim Alkhouri, M.D., FAASLD **Date & time:**November 5, 2026 at 12:00 pm - 1:00 pm MST

The presentations will be available for viewing by AASLD attendees and will be posted on our website under the “Events & Presentations” page shortly after the congress.

About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis and portal hypertension, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect”, “look forward”, “believe”, “hope” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not produce positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company’s current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.

Company Contact:

Jack Callicutt, Chief Financial Officer (678) 620-3186 [email protected]

Investors Relations Contacts: Kevin Gardner [email protected]

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.

<< Back

Prompts

Galectin Therapeutics Inc. (ticker GALT), listed in United States.

Company History

Date Change Detail
Mar 22, 2011 Renamed PRO PHARMACEUTICALS INC → GALECTIN THERAPEUTICS INC

ETFs Holding Galectin Therapeutics Inc.

ETF Weight in ETF Shares Market value As of
MEDX 1.14% 46,968 $ 217.932K Jun 30, 2026